Greenwich LifeSciences (GLSI) Competitors $12.67 -0.18 (-1.40%) (As of 01:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends GLSI vs. PBYI, ETTX, MITO, ABUS, ANAB, PHAT, ALT, ORIC, CRMD, and STOKShould you be buying Greenwich LifeSciences stock or one of its competitors? The main competitors of Greenwich LifeSciences include Puma Biotechnology (PBYI), Entasis Therapeutics (ETTX), Stealth BioTherapeutics (MITO), Arbutus Biopharma (ABUS), AnaptysBio (ANAB), Phathom Pharmaceuticals (PHAT), Altimmune (ALT), ORIC Pharmaceuticals (ORIC), CorMedix (CRMD), and Stoke Therapeutics (STOK). These companies are all part of the "medical" sector. Greenwich LifeSciences vs. Puma Biotechnology Entasis Therapeutics Stealth BioTherapeutics Arbutus Biopharma AnaptysBio Phathom Pharmaceuticals Altimmune ORIC Pharmaceuticals CorMedix Stoke Therapeutics Greenwich LifeSciences (NASDAQ:GLSI) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, community ranking, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment. Do analysts prefer GLSI or PBYI? Greenwich LifeSciences currently has a consensus price target of $38.00, suggesting a potential upside of 195.72%. Puma Biotechnology has a consensus price target of $7.00, suggesting a potential upside of 146.48%. Given Greenwich LifeSciences' higher probable upside, equities research analysts plainly believe Greenwich LifeSciences is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenwich LifeSciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in GLSI or PBYI? 4.2% of Greenwich LifeSciences shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 51.7% of Greenwich LifeSciences shares are held by company insiders. Comparatively, 23.7% of Puma Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community favor GLSI or PBYI? Puma Biotechnology received 541 more outperform votes than Greenwich LifeSciences when rated by MarketBeat users. Likewise, 66.99% of users gave Puma Biotechnology an outperform vote while only 41.18% of users gave Greenwich LifeSciences an outperform vote. CompanyUnderperformOutperformGreenwich LifeSciencesOutperform Votes741.18% Underperform Votes1058.82% Puma BiotechnologyOutperform Votes54866.99% Underperform Votes27033.01% Does the media refer more to GLSI or PBYI? In the previous week, Puma Biotechnology had 3 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 4 mentions for Puma Biotechnology and 1 mentions for Greenwich LifeSciences. Puma Biotechnology's average media sentiment score of 1.67 beat Greenwich LifeSciences' score of -0.60 indicating that Puma Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Greenwich LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Puma Biotechnology 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Very Positive Is GLSI or PBYI more profitable? Puma Biotechnology has a net margin of 9.56% compared to Greenwich LifeSciences' net margin of 0.00%. Puma Biotechnology's return on equity of 41.60% beat Greenwich LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets Greenwich LifeSciencesN/A -185.12% -164.27% Puma Biotechnology 9.56%41.60%10.71% Which has more risk and volatility, GLSI or PBYI? Greenwich LifeSciences has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Which has higher valuation and earnings, GLSI or PBYI? Puma Biotechnology has higher revenue and earnings than Greenwich LifeSciences. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGreenwich LifeSciencesN/AN/A-$8.89M-$0.80-16.06Puma Biotechnology$235.60M0.59$21.59M$0.485.92 SummaryPuma Biotechnology beats Greenwich LifeSciences on 12 of the 15 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get Greenwich LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLSI vs. The Competition Export to ExcelMetricGreenwich LifeSciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$167.86M$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-16.064.8587.8613.46Price / SalesN/A374.821,228.8287.66Price / CashN/A52.5939.5136.27Price / Book33.8210.216.946.30Net Income-$8.89M$153.61M$119.12M$225.93M7 Day Performance-5.45%-2.00%-1.84%-1.32%1 Month Performance-4.03%-7.47%-3.65%0.60%1 Year Performance21.23%31.80%31.64%26.23% Greenwich LifeSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLSIGreenwich LifeSciences1.914 of 5 stars$12.67-1.4%$38.00+199.9%+16.8%$166.61MN/A-15.843PBYIPuma Biotechnology4.2258 of 5 stars$2.94+3.5%$7.00+138.1%-27.0%$144.33M$235.60M5.92185Analyst ForecastNews CoverageETTXEntasis TherapeuticsN/A$2.19flatN/A+0.0%$104.80M$7M-1.9651MITOStealth BioTherapeuticsN/A$0.32flatN/AN/A$23.54M$21.09M-0.6229ABUSArbutus Biopharma2.8223 of 5 stars$3.50+1.7%$5.50+57.1%+87.0%$663.22M$18.14M-8.0073Analyst ForecastANABAnaptysBio2.4967 of 5 stars$21.35+5.1%$54.64+155.9%+40.0%$649.68M$17.16M-3.34100PHATPhathom Pharmaceuticals2.3252 of 5 stars$9.32+6.8%$22.50+141.4%+17.8%$637.30M$680,000.00-1.64110ALTAltimmune1.9389 of 5 stars$8.96+11.3%$20.00+123.2%+206.1%$637.24M$430,000.00-5.6350Analyst RevisionORICORIC Pharmaceuticals4.207 of 5 stars$8.98+2.7%$18.29+103.6%+22.4%$633.72MN/A-4.8680Analyst RevisionGap UpCRMDCorMedix2.6836 of 5 stars$10.44-2.8%$15.20+45.6%+184.1%$633.50M$60,000.00-13.2630Insider TradeSTOKStoke Therapeutics3.8497 of 5 stars$11.59+2.5%$20.83+79.8%+171.2%$613.92M$8.78M0.00100 Related Companies and Tools Related Companies PBYI Competitors ETTX Competitors MITO Competitors ABUS Competitors ANAB Competitors PHAT Competitors ALT Competitors ORIC Competitors CRMD Competitors STOK Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GLSI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Greenwich LifeSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Greenwich LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GLSI Stock Alerts